Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial

American Heart Journal

Volumn 148, Issue 1, 2004, Pages 105-

  Schwartz, Gregory G ^a,e   Bolognese, Michael A ^b   Tremblay, Benoit P ^c   Caplan, Richard ^d   Hutchinson, Howard ^d   Raza, Ali ^d   Cressman, Michael ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b Bethesda Health Research   (United States)

^c LAVAL UNIVERSITY   (Canada)

^d ASTRAZENECA   (United Kingdom)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ROSUVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; NUTRITIONAL REQUIREMENT; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 77951110669     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.01.020     Document Type: Article

References (21)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
2. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 335:1996;1001-1009
3. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307
4. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23
6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
7. Frolkis J.P., Zyzanski S.J., Schwartz J.M., et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 98:1998;851-855
8. Pearson T.A., Laurora I., Chu H., et al. The Lipid Treatment Assessment Project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 160:2000;459-467
9. Andrews T.C., Ballantyne C.M., Hsia J.A., et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 111:2001;185-191
10. Brown A.S., Bakker-Arkema R.G., Yellen L., et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 32:1998;665-672
11. Davidson M., Ma P., Stein E.A., et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 89:2002;268-275
12. Olsson A.G., Istad H., Luurila O., et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 144:2002;1044-1051
13. Second Joint Task Force. Prevention of coronary heart disease in clinical practice recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 19:1998;1434-1503
14. Remmell P.S., Gorder D.D., Hall Y., et al. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT), I use of a dietary monitoring tool. J Am Diet Assoc. 76:1980;351-356
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502
16. Schneck D.W., Knopp R.H., Ballantyne C.M., et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 91:2003;33-41
17. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia the DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 24:2001;1335-1341
18. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: a randomized controlled trial. JAMA. 285:2001;1711-1718
19. Brewer H.B. Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 92:(Suppl 4B):2003;23K-29K
20. Sueta C.A., Chowdhury M., Boccuzzi S.J., et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307
21. Nawrocki J.W., Weiss S.R., Davidson M.H., et al. Reduction of LDL-C by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682